Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China

    June 2023 in “ Advances in therapy ”
    Xinhua Zhang, Peng Zhang, Haibo Qiu … Jian Li
    Studysummary In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Platelet-Derived Growth Factor Signaling Modulates Adult Hair Follicle Dermal Stem Cell Maintenance and Self-Renewal npj Regenerative Medicine · 2017
    2. Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies Annals of Oncology · 2015
    3. RASopathic Alopecia: Hair Changes Associated with Vemurafenib Therapy Journal of The American Academy of Dermatology · 2015